Showcasing Groundbreaking Defense, Biomedical, Consumer and Communications Technology
Showcasing Groundbreaking Defense, Biomedical, Consumer and Communications Technology
- Nouscom Presents Positive Final Results from Completed Phase Ib/II Study of Neoantigen Immunotherapy NOUS-209 at AACR 2025, Demonstrating a Highly Potent and Durable Immune Response in Lynch Syndrome Carriers - April 29, 2025
- Facephi Ends 2024 Strong with Double-Digit Growth Across Key Metrics: TCV, ARR, Turnover and Ebitda - April 29, 2025
- KBL Impact Partners Calls for Corporate Collaboration to Transform Social Leadership - April 29, 2025